What is Zacks Research's Forecast for Revvity Q1 Earnings?

Key Points

• Zacks Research lowered its Q1 2028 EPS forecast for Revvity to $1.34 from $1.35 and maintains a “Hold” rating. The firm projects $1.63 EPS for Q2, $1.62 for Q3 and $6.51 for full-year 2028.
• Analyst sentiment remains mixed but broadly cautious: Revvity has five Buy ratings and 13 Hold ratings, resulting in a consensus “Hold” rating and an average price target of $124.43.
• Revvity recently exceeded quarterly expectations, reporting $1.41 EPS versus the $1.21 consensus and revenue of $729.69 million. Its shares opened at $156.95, near the company’s 12-month high of $169.06.

Revvity Inc. (NYSE:RVTY - Free Report) - Investment analysts at Zacks Research cut their Q1 2028 earnings per share (EPS) estimates for shares of Revvity in a research note issued on Wednesday, October 28th. Zacks Research analyst Team now forecasts that the company will earn $1.34 per share for the quarter, down from their prior forecast of $1.35. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Revvity's current full-year earnings is $5.36 per share. Zacks Research also issued estimates for Revvity's Q2 2028 earnings at $1.63 EPS, Q3 2028 earnings at $1.62 EPS and FY2028 earnings at $6.51 EPS.

A number of other brokerages also recently issued reports on RVTY. Weiss Ratings upgraded Revvity from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. William Blair started coverage on shares of Revvity in a research report on Monday, October 5th. They set an "outperform" rating for the company. Barclays raised their price objective on shares of Revvity from $115.00 to $160.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. TD Cowen increased their price target on Revvity from $130.00 to $175.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Finally, UBS Group started coverage on shares of Revvity in a report on Wednesday, September 9th. They set a "neutral" rating and a $140.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $124.43.

Revvity Price Performance

NYSE RVTY opened at $156.95 on Monday. The stock has a market capitalization of $17.51 billion, a PE ratio of 74.74, a price-to-earnings-growth ratio of 2.86 and a beta of 1.08. The company has a 50 day moving average price of $144.54 and a two-hundred day moving average price of $112.15. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. Revvity has a 12-month low of $81.22 and a 12-month high of $169.06.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same period last year, the firm posted $1.18 EPS. Revvity's revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS.

Insider Activity at Revvity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the company's stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the transaction, the insider directly owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tajinder Vohra sold 7,330 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the transaction, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,045 shares of company stock worth $1,281,439 in the last ninety days. Corporate insiders own 0.85% of the company's stock.

Hedge Funds Weigh In On Revvity

Hedge funds and other institutional investors have recently modified their holdings of the company. Chicago Partners Investment Group LLC lifted its stake in shares of Revvity by 6.8% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 3,922 shares of the company's stock worth $623,000 after purchasing an additional 251 shares during the last quarter. Rakuten Investment Management Inc. increased its position in shares of Revvity by 8.0% during the third quarter. Rakuten Investment Management Inc. now owns 12,773 shares of the company's stock worth $1,951,000 after acquiring an additional 945 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Revvity by 35.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 67,485 shares of the company's stock worth $10,318,000 after purchasing an additional 17,629 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Revvity during the third quarter worth about $5,522,000. Finally, ProShare Advisors LLC raised its stake in shares of Revvity by 1.1% during the 3rd quarter. ProShare Advisors LLC now owns 21,941 shares of the company's stock worth $3,355,000 after buying an additional 232 shares during the last quarter. 86.65% of the stock is owned by institutional investors.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.